AML-288: The Combination of Gemtuzumab Ozogamicin and Azacitidine in the Treatment of Relapsed and Refractory AML

Budaeva, Irina; Zaytsev, Daniil; Shatilova, Aleksina; Tochenaya, Elena; Петров, А. С.; Vabishchevich, Raisa; Motorin, Dmitriy; Badaev, Renat; Иванов, В. В.; Богданов, Константин; Mirolyubova, Yulia; Nikulina, Tatiana; Alekseeva, Yulia; Zaritskey, Andrey; Girshova, Larisa

doi:10.1016/s2152-2650(21)01716-x

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…74 Further investigation into the efficacy of GO, both with and without HMA, as a low-intensity treatment regimen, should be considered in future clinical trials for patients with relapsed and refractory AML who are ineligible for intensive therapies. 75,76 In addition, the panel agreed that consolidation therapy could be administered on the basis of the 2022 ELN risk stratification. 2,4 In choosing 10 panel members, the study aimed to ensure a representation of diverse social and clinical practices across countries, enhancing the model's applicability in various health care settings.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Consensus-Based Guidelines for Acute Myeloid Leukemia Management in Gulf Cooperation Council Countries: Addressing Unmet Regional Needs and the Changing AML Landscape

Al-Khabori,

Alhuraiji,

Alam

et al. 2024

JCO Glob Oncol

View full text Add to dashboard Cite

PURPOSE AML is a heterogeneous hematologic malignancy. Region-specific recommendations for AML management can enhance patient outcomes. This article aimed to develop recommendations for the Gulf Cooperation Council (GCC) countries. METHODS Ten AML panel members from Kuwait, Oman, Qatar, and the United Arab Emirates (KOQU) participated in a modified two-round Delphi process. The panel first identified the unmet regional needs and finalized a list of core variables. Next, they voted on iterative statements drawn from international recommendations and provided feedback via a questionnaire. Consensus voting ≤70% was discussed, and additional clinical decision making statements were suggested. At round closure, a consensus vote took place on revised statements. RESULTS The panel reached ≥97.8% consensus on AML management. The panel agreed to use international risk stratification categories for personalized treatment of AML. The presence of ≥10% blasts for recurrent genetic abnormalities was required for a diagnosis of AML. Key consensus was reached for different treatment stages. The panel noted that older patients pose a challenge because of poor cytogenetics and genetic anomalies and require different treatment approaches. The panel recommended venetoclax-hypomethylating agents; fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor; and targeted therapy for AML relapsed/refractory disease. Supportive care is considered on the basis of prevailing organisms and drug resistance. CONCLUSION The GCC KOQU's consensus-based recommendations for managing AML include an evidence-based and region-specific framework.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Consensus-Based Guidelines for Acute Myeloid Leukemia Management in Gulf Cooperation Council Countries: Addressing Unmet Regional Needs and the Changing AML Landscape

Al-Khabori,

Alhuraiji,

Alam

et al. 2024

JCO Glob Oncol

View full text Add to dashboard Cite

show abstract

“…In a retrospective study on 17 R/R AML patients, the combination of GO and azacitidine provided an overall response rate of 76.9%, emerging as a possible bridge to transplant treatment [ 92 ].…”

Section: Harnessing Immunitymentioning

confidence: 99%

New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy

Andreozzi

Massaro

Wittnebel

et al. 2022

IJMS

View full text Add to dashboard Cite

For decades, intensive chemotherapy (IC) has been considered the best therapeutic option for treating acute myeloid leukemia (AML), with no curative option available for patients who are not eligible for IC or who have had failed IC. Over the last few years, several new drugs have enriched the therapeutic arsenal of AML treatment for both fit and unfit patients, raising new opportunities but also new challenges. These include the already approved venetoclax, the IDH1/2 inhibitors enasidenib and ivosidenib, gemtuzumab ozogamicin, the liposomal daunorubicin/cytarabine formulation CPX-351, and oral azacitidine. Venetoclax, an anti BCL2-inhibitor, in combination with hypomethylating agents (HMAs), has markedly improved the management of unfit and elderly patients from the perspective of improved quality of life and better survival. Venetoclax is currently under investigation in combination with other old and new drugs in early phase trials. Recently developed drugs with different mechanisms of action and new technologies that have already been investigated in other settings (BiTE and CAR-T cells) are currently being explored in AML, and ongoing trials should determine promising agents, more synergic combinations, and better treatment strategies. Access to new drugs and inclusion in clinical trials should be strongly encouraged to provide scientific evidence and to define the future standard of treatment in AML.

show abstract

“…vizsgálat folyamatban van. Egy retrospektív, 17 R/R AML-es beteget vizsgáló tanulmányban a GO þ AZA kombináció 76,9%-os terápiás választ eredményezetett, az eredmények alapján a GO allo-SCT előtti bridgingként való felhasználása is felmerülhet [92]. Egy fázis Ib vizsgálatban a GO þ VEN kombináció biztonságos volt, a hatékonyság tesztelése még folyamatban van [93].…”

Section: Monoklonális Antitestek (Mab)unclassified

Az akut mieloid leukémia kezelésének új lehetőségei: út a személyre szabott terápiás stratégiák felé

Szakács

Alizadeh

2022

Hemat

View full text Add to dashboard Cite

Az akut mieloid leukémia (AML) kezelésének arany standardja évtizedek óta az intenzív kemoterápia, azonban az erre nem alkalmas vagy refrakter betegeknél jelenleg nincs más kuratív lehetőség. Az utóbbi évek gyógyszerfejlesztése a jó és a rosszabb általános állapotú eseteknél is kibővítette a terápiás armamentáriumot, új terápiás lehetőségeket és kihívásokat is teremtve. Az új szerek közé tartozik például a venetoclax, az IDH1/2 gátló ivosidenib és enasidenib, a gemtuzumab ozogamicin, a liposzómális daunorubicin/citarabin (CPX-351) és az orálisan adható azacitidin. A venetoclax, mint BCL2-inhibitor, hipometiláló ágenssel együtt adva jelentősen javítja az idősebb, rosszabb általános állapotú AML-es esetek életminőségét, életkilátásait. Jelenleg is számos korai fázisú tanulmány vizsgálja a régebbi és újabb szerekkel kombinált venetoclax hatásait. Más mechanizmusokon alapuló, újabb gyógyszeres és nem gyógyszeres terápiás modalitások (pl. BiTE és CAR-T sejtek) is fejlesztés alatt állnak, a jelenleg futó klinikai vizsgálatok célja a hatékony szerek és szerkombinációk azonosítása. Az új terápiás modalitások használata mellett a betegek klinikai vizsgálatokba történő beválogatása javasolt, mivel az ezekből származó eredmények, tapasztalatok szolgáltathatnak tudományos bizonyítékot a jövő arany standard kezelésének megtalálásában.

show abstract

AML-288: The Combination of Gemtuzumab Ozogamicin and Azacitidine in the Treatment of Relapsed and Refractory AML

Cited by 4 publications

References 0 publications

Consensus-Based Guidelines for Acute Myeloid Leukemia Management in Gulf Cooperation Council Countries: Addressing Unmet Regional Needs and the Changing AML Landscape

Consensus-Based Guidelines for Acute Myeloid Leukemia Management in Gulf Cooperation Council Countries: Addressing Unmet Regional Needs and the Changing AML Landscape

New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy

Az akut mieloid leukémia kezelésének új lehetőségei: út a személyre szabott terápiás stratégiák felé

Contact Info

Product

Resources

About